ProCE Banner Series

Time to Move the Goalposts? Examining Strategies to Advance HBV Management

Join expert faculty as they provide education, perspectives, and recommendations for early HBV treatment and the evolving role of quantitative HBsAg monitoring in people living with chronic hepatitis B.

  AMA
Who Should Attend

This program is intended for physicians, including hepatologists and gastroenterologists, and other healthcare professionals involved in the care of patients with chronic hepatitis B. 

All Events

Time to Move the Goalposts? Examining Strategies to Advance HBV Management

Past Events

November

11

2023

12:30 PM - 2:00 PM Eastern Time (ET)

In-personVirtual

John B. Hynes Veterans Memorial Convention Center, 900 Boylston St, Boston, Massachusetts 02115

Faculty

ProCE Banner Faculty
Ira M. Jacobson, MD

Vincent Astor Professor of Medicine
Chief, Division of Gastroenterology and Hepatology
Department of Medicine
Weill Cornell Medical College
Attending Physician
Division of Gastroenterology and Hepatology
Department of Medicine
NewYork-Presbyterian Hospital
New York, New York

ProCE Banner Faculty
Tatyana Kushner, MD, MSCE

Associate Professor
Division of Gastroenterology/ Hepatology
Department of Obstetrics & Gynecology
Weill Cornell Medicine
New York, New York

ProCE Banner Faculty
Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Topics

Welcome, Opening Remarks, and Baseline Assessment (5 min)

Are We Treating HBV Early Enough? (40 min)

Should Quantitative HBsAg Monitoring Be Routinely Used in Clinical Practice? (35 min)

Conclusion and Question and Answer Session (15 min)

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve learners’ knowledge and competence regarding key strategies for advancing the management of HBV, including early initiation of therapy and the role of quantitative HBsAg monitoring. 

Target Audience
This program is intended for physicians, including hepatologists and gastroenterologists, and other healthcare professionals involved in the care of patients with chronic hepatitis B. 

Learning Objectives

  • Select appropriate candidates for early HBV treatment after weighing drug-related considerations, cost-benefit considerations, and impact on patient outcomes
  • Outline the role of quantitative HBsAg in monitoring patients with CHB, including evaluating disease status and predicting disease progression, treatment response, and functional cure
  • Identify current and future clinical scenarios where quantitative HBsAg monitoring is beneficial to patient management

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Presented for attendees of The Liver Meeting® 2023. This event/function is provided by Clinical Care Options and supported by GlaxoSmithKline. This is not an official event/function of the American Association for the Study of Liver Diseases.